ha14-1 has been researched along with Leukemia in 4 studies
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Importantly, low-concentration HA14-1 (5 muM) was nontoxic to normal colony-forming cells, whereas it enhanced the cytotoxicity of the antileukemia drug cytarabine in Bcl-2-positive lymphoblastic leukemia cells." | 7.72 | HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. ( Cox, J; Johnson, L; Lickliter, JD; McHugh, G; Tan, J; Wickham, NW; Wood, F; Wood, NJ, 2003) |
| " Importantly, low-concentration HA14-1 (5 muM) was nontoxic to normal colony-forming cells, whereas it enhanced the cytotoxicity of the antileukemia drug cytarabine in Bcl-2-positive lymphoblastic leukemia cells." | 3.72 | HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. ( Cox, J; Johnson, L; Lickliter, JD; McHugh, G; Tan, J; Wickham, NW; Wood, F; Wood, NJ, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, CY | 1 |
| Park, C | 1 |
| Lee, JH | 1 |
| Chung, KT | 1 |
| Kwon, TK | 1 |
| Kim, GY | 2 |
| Choi, BT | 1 |
| Choi, YH | 2 |
| Moon, DO | 1 |
| Kim, MO | 1 |
| Kang, SH | 1 |
| Park, SY | 1 |
| Lickliter, JD | 1 |
| Wood, NJ | 1 |
| Johnson, L | 1 |
| McHugh, G | 1 |
| Tan, J | 1 |
| Wood, F | 1 |
| Cox, J | 1 |
| Wickham, NW | 1 |
| Tian, D | 1 |
| Das, SG | 1 |
| Doshi, JM | 1 |
| Peng, J | 1 |
| Lin, J | 1 |
| Xing, C | 1 |
4 other studies available for ha14-1 and Leukemia
| Article | Year |
|---|---|
Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Benzopyrans; Caspase Inh | 2009 |
HA14-1 sensitizes TNF-alpha-induced apoptosis via inhibition of the NF-kappaB signaling pathway: involvement of reactive oxygen species and JNK.
Topics: Apoptosis; Benzopyrans; Cell Line, Tumor; DNA, Neoplasm; Enzyme Activation; Humans; Leukemia; MAP Ki | 2010 |
HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death.
Topics: Apoptosis; Benzopyrans; Blast Crisis; Bone Marrow Cells; Cell Death; Cell Survival; Cytarabine; Drug | 2003 |
sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Ben | 2008 |